TCGA-BT-A20R-01A-12R-A16R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 5.05913272
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- ANGIOGENESIS+0.400
- KRAS_SIGNALING_UP+0.320
- COAGULATION+0.290
- COMPLEMENT+0.290
- PROTEIN_SECRETION+0.270
- UV_RESPONSE_DN+0.270
- ADIPOGENESIS+0.210
- ANDROGEN_RESPONSE+0.190
- MYOGENESIS+0.190
Top 10 suppressed
- MYC_TARGETS_V2-0.470
- WNT_BETA_CATENIN_SIGNALING-0.320
- DNA_REPAIR-0.260
- MYC_TARGETS_V1-0.260
- G2M_CHECKPOINT-0.220
- P53_PATHWAY-0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.190
- PI3K_AKT_MTOR_SIGNALING-0.150
- INTERFERON_ALPHA_RESPONSE-0.130
- NOTCH_SIGNALING-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290943 | — | — | 0.823 |
| 2 | MBCProject_3122_T1_RNA | — | A | 0.822 |
| 3 | TCGA-FD-A3SL-01A-21R-A22U-07 | — | — | 0.813 |
| 4 | 27a08af2-4626-4bf9-bdf6-a6ba644a53a2 | — | — | 0.804 |
| 5 | SRR8518186 | — | A | 0.799 |
| 6 | SRR35579842 | — | A | 0.794 |
| 7 | TCGA-50-5930-01A-11R-1755-07 | — | cohortA4 | 0.783 |
| 8 | ERR2598110 | fetal | fetal | 0.777 |
| 9 | TCGA-AC-A23E-01A-11R-A157-07 | — | A | 0.775 |
| 10 | TCGA-CN-4740-01A-01R-1436-07 | — | — | 0.775 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |